Lead Plaintiff Deadline: August 02, 2021
Please Upload related files below
Fill in below.
Looking for more?
the Company’s Phase 2a trial results failed to live up to the Company’s expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322’s potential. These statements materially misled the market and artificially inflated the value of Frequency’s common stock.
In order to be included in the lawsuit, you must have incurred a loss on shares of Frequency Therapeutics purchased during the class period listed above.
If you suffered a loss in Frequency Therapeutics during the relevant time frame, you have until August 02, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.